Approved

Pharmazz

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Lyfaquin®, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in India

Lead Product(s): Centhaquine

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Lyfaquin

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 20, 2020

Details:

Lyfaquin® increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhancing tissue blood perfusion by arterial dilatation (sympatholytic function due to central alpha-2A adrenergic stimulation).

MediWound

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns

Lead Product(s): Bromelain

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: NexoBrid

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The BLA submission includes a comprehensive set of manufacturing data, multiple preclinical and clinical studies including the pivotal U.S. Phase 3 study of NexoBrid in adult patients with deep partial and full-thickness thermal burns.

Pharmazz

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Pharmazz Receives Marketing Authorization for Lyfaquin™ (centhaquine) from Indian Regulatory Agency

Lead Product(s): Centhaquine

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 14, 2020

Details:

Centhaquine's pivotal phase III study in India in hypovolemic shock demonstrated a transformational improvement over standard of care in increasing blood pressure and reducing blood lactate levels.

Genfa Medica

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements with Genfa Medica

Lead Product(s): Bromelain

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: MediWound

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 04, 2020

Details:

MediWound granted GENFA MEDICA SA right to distribute NexoBrid® in France and Switzerland and Specialty Therapeutics the right to market and distribute NexoBrid in Greece, Bulgaria, Malta and Cyprus.

Abigo Medical AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

Essity Acquires 75% of the Medical Solutions Company ABIGO Medical AB

Lead Product(s): Dialkylcarbamoylchloride

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Essity

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition February 27, 2020

Details:

ABIGO Medical has leading innovations in advanced wound care that reduce the spread of bacteria without increasing resistance to antibiotics.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals Announces Proposed Public Offering

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Guggenheim Securities

Deal Size: $21.7 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 20, 2020

Details:

EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® and YUTIQ® and for general corporate purposes.

EyePoint Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

3rd Formulation & Drug Delivery USA

Participation Not Confirmed

Update your events

EyePoint Pharmaceuticals and Vision Center Network Ink Agreement

Lead Product(s): Dexamethasone

Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Vision Center Network of America

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement February 18, 2020

Details:

The agreement will enable VCNA physicians to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.